Àlex Teulé

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

Enrique Grande, Jaume Capdevila, Daniel Castellano et al. · Annals of Oncology · 2015 · 155 citations · Full text

Open-label Trial, Endocrine Oncology, Surgical Oncology +10

Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification

Michael T. Parsons, Emma Tudini, Hongyan Li et al. · Human Mutation · 2019 · 148 citations · Full text

Genetics, Genetic Epidemiology, Pathology +25

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

Fergus J. Couch, Karoline Kuchenbaecker, Kyriaki Michailidou et al. · Nature Communications · 2016 · 120 citations · Full text

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

Jaume Capdevila, Nicola Fazio, Carlos López et al. · Journal of Clinical Oncology · 2021 · 103 citations · Full text

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers

Antonis C. Antoniou, Karoline Kuchenbaecker, Penny Soucy et al. · Breast Cancer Research · 2012 · 95 citations · Full text